본문

서브메뉴

Improving Access to Alcohol Use Disorder Pharmacotherapy in Hepatology: A Quality Improvement Initiative
Improving Access to Alcohol Use Disorder Pharmacotherapy in Hepatology: A Quality Improvem...
Improving Access to Alcohol Use Disorder Pharmacotherapy in Hepatology: A Quality Improvement Initiative

상세정보

자료유형  
 학위논문 서양
최종처리일시  
20260202103704
ISBN  
9798280722279
DDC  
610.73
저자명  
Collier, Summer Brianne.
서명/저자  
Improving Access to Alcohol Use Disorder Pharmacotherapy in Hepatology: A Quality Improvement Initiative
발행사항  
[Sl] : University of California, Los Angeles, 2025
발행사항  
Ann Arbor : ProQuest Dissertations & Theses, 2025
형태사항  
60 p
주기사항  
Source: Dissertations Abstracts International, Volume: 86-12, Section: B.
주기사항  
Advisor: Robbins, Wendie A.
학위논문주기  
Thesis (D.N.P.)--University of California, Los Angeles, 2025.
초록/해제  
요약Background: Alcohol-associated liver disease (ALD) is the leading cause of liver-related morbidity and mortality in North America. Despite strong evidence supporting pharmacologic treatment for alcohol use disorder (AUD), pharmacotherapy remains significantly underutilized in hepatology settings. Identified barriers include provider unfamiliarity, safety concerns in cirrhosis, and system-level workflow limitations. Aim: To increase prescription rates of AUD pharmacotherapy in a high-volume hepatology clinic through targeted, scalable quality improvement interventions integrated into existing workflows. Methods: This single-center, quasi-experimental quality improvement study compared two cohorts of adults with ALD and active alcohol use seen in a hepatology clinic: pre-intervention (January-March 2023; n=143) and post-intervention (January-March 2025; n=175). Interventions included provider education, standardized alcohol screening, integration of decision-support tools (including a prescribing algorithm and documentation templates), and improved access to long-acting injectable medication. Outcomes were assessed via retrospective chart review. Multivariable logistic regression using backward stepwise elimination was performed to identify predictors of alcohol use disorder pharmacotherapy initiation. Results: AUD pharmacotherapy prescribing increased significantly from 10% pre-intervention to 43% post-intervention (p0.00001). Documented discussions of pharmacotherapy rose from 33% to 80% (p0.00001), while deferral to psychiatry or primary care decreased from 7% to 1% (p=0.006), indicating enhanced provider engagement and prescribing autonomy. Among those prescribed treatment, use of first-line agents such as oral naltrexone and acamprosate increased, and long-acting medication (Vivitrol) was newly adopted. Regression analysis (AUC=0.77) identified three independent predictors of pharmacotherapy initiation: post-intervention year (OR=6.03, 95% CI [3.20-11.34], p0.001), recent positive phosphatidylethanol (PEth) test (OR=2.44 vs. no PEth, 95% CI [1.28-4.64], p=0.007), and a trend toward lower Child-Turcotte Pugh (CTP) scores (OR=0.87, 95% CI [0.75-1.00], p=0.057). Model deviance R² was 16.2%, reflecting moderate fit likely influenced by unmeasured variables such as patient readiness for behavioral change. Conclusion: Embedded, interdisciplinary quality improvement interventions can substantially increase alcohol use disorder pharmacotherapy rates in hepatology without requiring structural clinic overhauls. This approach enhanced provider autonomy, reduced unnecessary deferrals, and optimized the use of clinical tools such as PEth testing. Findings support broader implementation of pragmatic, evidence-based strategies to improve alcohol use disorder care for patients with alcohol-associated liver disease in specialty settings.
일반주제명  
Nursing
일반주제명  
Pharmacology
일반주제명  
Medicine
일반주제명  
Clinical psychology
키워드  
Alcohol associated liver disease
키워드  
Alcohol use disorder
키워드  
Nurse practitioners
키워드  
Nurse-led
키워드  
Pharmacotherapy
키워드  
Quality improvement
기타저자  
University of California, Los Angeles Nursing 0597
기본자료저록  
Dissertations Abstracts International. 86-12B.
전자적 위치 및 접속  
로그인 후 원문을 볼 수 있습니다.

MARC

 008260126s2025        us                              c    eng  d
■001000017358242
■00520260202103704
■006m          o    d                
■007cr#unu||||||||
■020    ▼a9798280722279
■035    ▼a(MiAaPQ)AAI32113345
■040    ▼aMiAaPQ▼cMiAaPQ
■0820  ▼a610.73
■1001  ▼aCollier,  Summer  Brianne.
■24510▼aImproving  Access  to  Alcohol  Use  Disorder  Pharmacotherapy  in  Hepatology:  A  Quality  Improvement  Initiative
■260    ▼a[Sl]▼bUniversity  of  California,  Los  Angeles▼c2025
■260  1▼aAnn  Arbor▼bProQuest  Dissertations  &  Theses▼c2025
■300    ▼a60  p
■500    ▼aSource:  Dissertations  Abstracts  International,  Volume:  86-12,  Section:  B.
■500    ▼aAdvisor:  Robbins,  Wendie  A.
■5021  ▼aThesis  (D.N.P.)--University  of  California,  Los  Angeles,  2025.
■520    ▼aBackground:  Alcohol-associated  liver  disease  (ALD)  is  the  leading  cause  of  liver-related  morbidity  and  mortality  in  North  America.  Despite  strong  evidence  supporting  pharmacologic  treatment  for  alcohol  use  disorder  (AUD),  pharmacotherapy  remains  significantly  underutilized  in  hepatology  settings.  Identified  barriers  include  provider  unfamiliarity,  safety  concerns  in  cirrhosis,  and  system-level  workflow  limitations.  Aim:  To  increase  prescription  rates  of  AUD  pharmacotherapy  in  a  high-volume  hepatology  clinic  through  targeted,  scalable  quality  improvement  interventions  integrated  into  existing  workflows.  Methods:  This  single-center,  quasi-experimental  quality  improvement  study  compared  two  cohorts  of  adults  with  ALD  and  active  alcohol  use  seen  in  a  hepatology  clinic:  pre-intervention  (January-March  2023;  n=143)  and  post-intervention  (January-March  2025;  n=175).  Interventions  included  provider  education,  standardized  alcohol  screening,  integration  of  decision-support  tools  (including  a  prescribing  algorithm  and  documentation  templates),  and  improved  access  to  long-acting  injectable  medication.  Outcomes  were  assessed  via  retrospective  chart  review.  Multivariable  logistic  regression  using  backward  stepwise  elimination  was  performed  to  identify  predictors  of  alcohol  use  disorder  pharmacotherapy  initiation.  Results:  AUD  pharmacotherapy  prescribing  increased  significantly  from  10%  pre-intervention  to  43%  post-intervention  (p0.00001).  Documented  discussions  of  pharmacotherapy  rose  from  33%  to  80%  (p0.00001),  while  deferral  to  psychiatry  or  primary  care  decreased  from  7%  to  1%  (p=0.006),  indicating  enhanced  provider  engagement  and  prescribing  autonomy.  Among  those  prescribed  treatment,  use  of  first-line  agents  such  as  oral  naltrexone  and  acamprosate  increased,  and  long-acting  medication  (Vivitrol)  was  newly  adopted.  Regression  analysis  (AUC=0.77)  identified  three  independent  predictors  of  pharmacotherapy  initiation:  post-intervention  year  (OR=6.03,  95%  CI  [3.20-11.34],  p0.001),  recent  positive  phosphatidylethanol  (PEth)  test  (OR=2.44  vs.  no  PEth,  95%  CI  [1.28-4.64],  p=0.007),  and  a  trend  toward  lower  Child-Turcotte  Pugh  (CTP)  scores  (OR=0.87,  95%  CI  [0.75-1.00],  p=0.057).  Model  deviance  R²  was  16.2%,  reflecting  moderate  fit  likely  influenced  by  unmeasured  variables  such  as  patient  readiness  for  behavioral  change.  Conclusion:  Embedded,  interdisciplinary  quality  improvement  interventions  can  substantially  increase  alcohol  use  disorder  pharmacotherapy  rates  in  hepatology  without  requiring  structural  clinic  overhauls.  This  approach  enhanced  provider  autonomy,  reduced  unnecessary  deferrals,  and  optimized  the  use  of  clinical  tools  such  as  PEth  testing.  Findings  support  broader  implementation  of  pragmatic,  evidence-based  strategies  to  improve  alcohol  use  disorder  care  for  patients  with  alcohol-associated  liver  disease  in  specialty  settings.
■590    ▼aSchool  code:  0031.
■650  4▼aNursing
■650  4▼aPharmacology
■650  4▼aMedicine
■650  4▼aClinical  psychology
■653    ▼aAlcohol  associated  liver  disease
■653    ▼aAlcohol  use  disorder
■653    ▼aNurse  practitioners
■653    ▼aNurse-led
■653    ▼aPharmacotherapy
■653    ▼aQuality  improvement
■690    ▼a0569
■690    ▼a0564
■690    ▼a0622
■690    ▼a0419
■71020▼aUniversity  of  California,  Los  Angeles▼bNursing  0597.
■7730  ▼tDissertations  Abstracts  International▼g86-12B.
■790    ▼a0031
■791    ▼aD.N.P.
■792    ▼a2025
■793    ▼aEnglish
■85640▼uhttp://www.riss.kr/pdu/ddodLink.do?id=T17358242▼nKERIS▼z이  자료의  원문은  한국교육학술정보원에서  제공합니다.

미리보기

내보내기

chatGPT토론

Ai 추천 관련 도서


    신착도서 더보기
    최근 3년간 통계입니다.

    소장정보

    • 예약
    • 소재불명신고
    • 나의폴더
    • 우선정리요청
    • 비도서대출신청
    • 야간 도서대출신청
    소장자료
    등록번호 청구기호 소장처 대출가능여부 대출정보
    TF15056 전자도서 대출가능 마이폴더 부재도서신고 비도서대출신청 야간 도서대출신청

    * 대출중인 자료에 한하여 예약이 가능합니다. 예약을 원하시면 예약버튼을 클릭하십시오.

    해당 도서를 다른 이용자가 함께 대출한 도서

    관련 인기도서

    로그인 후 이용 가능합니다.